Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 37Lung Neoplasms 12Small Cell Lung Carcinoma 5Nonsquamous Non-Small Cell Lung Cancer 2Neoplasms 2Carcinoma 2Advanced Lung Cancer 2Thoracic Neoplasms 1Stomach Neoplasms 1Squamous Non-Small Cell Lung Cancer SqNSCLC 1Squamous NSCLC 1Squamous Cell Non-small Cell Lung Cancer 1Small Cell Lung Cancer Extensive Stage 1SCLC 1Respiratory Tract Diseases 1Resectable Non-small Cell Lung Cancer 1Resectable NSCLC 1Radiation Pneumonitis 1Osteosarcoma 1Non-small Cell Lung Cancer Metastatic 1Non-Squamous Non-Small Cell Lung Cancer 1NSCLC 1Multiple Primary Lung Cancer 1Lung Diseases 1Locally Advanced Non-Small Cell Lung Cancer 1IIIA Stage Non-small Cell Lung Cancer 1High-Risk Resectable NSCLC 1Brain Neoplasms 1Advanced Non-squamous Non-Small-Cell Lung Cancer 1Advanced Non-Small Cell Lung Cancer 1

Interventions

Carboplatin 2sintilimab 1pembrolizumab 1HLX07 1Gemcitabine 1Cisplatin 14-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Squamous NSCLC × sintilimab × Thoracic × Clear all
NCT03629925 2023-02-28

Sintilimab in Combination With Gemcitabine and Platinum-Based Chemotherapy as First-Line Therapy for Advanced or Metastatic Squamous NSCLC

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3 Completed
357 enrolled 14 charts
Thoracic

Squamous NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡